Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

New Cancer Targets, New Therapeutics and Clinical Trials

Merging technological innovations and new knowledge about basic cancer biology, cancer researchers now target specific molecules involved in critical chemical pathways of cancerous cells.

The approach opens the door to more effective drug therapies and treatment strategies, advances that will be the focus of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – the premier international meeting featuring novel cancer therapeutics – to be held October 22 to 26 at the Moscone West Convention Center, San Francisco, California.

Each year, the American Association for Cancer Research (AACR), jointly with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC), brings together scientists and other professionals from around the world seeking to share the latest information in this field, otherwise known as molecular targets of cancer.

“We are in the midst of a remarkable period of exploration and experimentation in cancer research, with tools and technologies in place to put into practice what might only have been theory just a few short years ago,” said Sara A. Courtneidge, Ph.D., a co-chairperson on the Scientific Committee for the meeting and professor at The Burnham Institute for Medical Research in La Jolla, California. “This meeting – where researchers can talk face-to-face about the latest information and reports from continuing studies – is a necessary part of the process of scientific discovery.”

More than 3,000 scientists and clinicians – from the laboratories of universities, medical centers and pharmaceutical companies worldwide – are gathering in San Francisco to present and discuss novel cancer research findings. The AACR has selected 24 scientific abstracts for presentation by their authors in five press briefings, each highlighting a critical or emerging area of molecular target research, such as:

•The promising results of a Phase I trial of a novel antibody against the insulin-like growth factor receptor in patients with advanced solid tumors have prompted researchers based at the University of Colorado Health Sciences Center to initiate a Phase II trial.

•Screening the NCI’s vast Natural Products Repository for the next Taxol is a complicated task with innumerable rewards. The National Cancer Institute maintains the world’s largest database of natural compounds, representing biologically diverse organisms from across the globe. However, screening these unpurified samples involves complicated chemistry. NCI researchers have used advanced screening techniques to uncover a way of “throwing a monkey wrench” into a cell process responsible for a great percentage of human cancers.

•Combining therapies to deliver a “one-two punch” against cancer is rapidly coming to fruition in cancer research. Combining approved targeted treatments with other existing and emerging therapies may enhance the effects of the individual treatments, alone. Researchers at the University of Manchester have found, for example, that combining radiotherapy with an inhibitor under development can prevent cancer cells from becoming resistant to radiation.

•The discovery of new targets for cancer therapeutics, when combined with high-throughput screening techniques, has made it possible for researchers to rapidly develop new drug candidates that might serve as therapies in multiple cancers. Scientists from ARIUS Research have created a novel antibody that effectively “de-cloaks” cancer cells, enabling the immune system to recognize and attack tumors. Likewise, researchers from University College London have identified the first small molecule inhibitors of protein kinase D, a frequently deregulated pathway in many cancers.

Nicole Heine | alfa
Further information:

More articles from Event News:

nachricht Virtual reality conference comes to Reutlingen
19.03.2018 | Fraunhofer-Institut für Arbeitswirtschaft und Organisation IAO

nachricht Ultrafast Wireless and Chip Design at the DATE Conference in Dresden
16.03.2018 | Technische Universität Dresden

All articles from Event News >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

TIB’s Visual Analytics Research Group to develop methods for person detection and visualisation

19.03.2018 | Information Technology

Tiny implants for cells are functional in vivo

19.03.2018 | Interdisciplinary Research

Science & Research
Overview of more VideoLinks >>>